Pancreatic beta cells reveal how ageing, type 2 diabetes reshape insulin response

Research has shown that insulin-producing beta cells adapt across a lifetime through gradual epigenetic changes, with type 2 diabetes appearing to intensify the same response under chronic metabolic stress

Pancreatic beta cells may preserve normal blood sugar across much of adult life through gradual epigenetic changes that help them to maintain insulin production, according to research that has offered a more detailed view of how these cells adapt during ageing and type 2 diabetes (T2DM).

The study has suggested that beta cells respond to rising metabolic demand through changes in regulatory regions of the genome that support cell identity and function. In T2DM, a similar pattern appeared to be accelerated, consistent with a compensatory response to sustained metabolic stress that may ultimately become insufficient.

The work was led by Dr Dana Avrahami-Tzfati of the Hebrew University of Jerusalem, Israel, in collaboration with Dr Elisabetta Manduchi and Professor Klaus Kaestner of the University of Pennsylvania, Philadelphia, USA.

More than half a billion people worldwide are living with diabetes, most of whom have T2DM, a chronic metabolic condition linked to ageing populations, altered diets, sedentary behaviour and other lifestyle factors. Although T2DM is widespread, the precise cell-specific mechanisms that govern beta-cell adaptation and eventual functional decline are still only partially understood.

Pancreatic beta cells produce and secrete insulin, the hormone that allows the body to regulate blood glucose after meals and during fasting. As people age, insulin resistance often increases, meaning that tissues such as muscle, liver and fat become less responsive to insulin. In many individuals, however, blood sugar remains within the normal range because beta cells compensate by sustaining or increasing insulin output. The novel study has examined how this long-term compensation may be reflected in the epigenome.

The researchers used cell-type-specific methylome data from the Human Pancreas Analysis Program (HPAP) to map molecular patterns in pancreatic cells. HPAP is a US-based research initiative to study human pancreatic tissue in fine molecular detail in order to understand how diabetes develops.

The team’s analysis focused on DNA methylation, a relatively stable chemical mark on DNA that helps to regulate gene activity across time without altering the underlying genetic sequence. By examining methylation patterns in different pancreatic cell types, the researchers were able to distinguish age-related changes in insulin-producing beta cells from those seen in neighbouring cells.

In healthy individuals, the team identified a gradual process of age-related demethylation in beta cells. Demethylation refers to the removal or reduction of methyl groups from DNA. In this context, it occurred in regulatory regions of the genome associated with beta-cell identity and insulin secretion. The pattern suggested that beta cells may use this epigenetic adjustment to preserve the activity of genes needed for long-term glucose control.

By contrast, alpha cells, which produce the hormone glucagon, followed a different ageing trajectory. Rather than to show the same demethylation pattern, alpha cells showed a slight increase in methylation. Glucagon acts in opposition to insulin by helping to raise blood glucose when levels fall too low. The divergence between beta cells and alpha cells indicated that ageing affects pancreatic cell types in distinct ways, with beta cells showing a particularly strong capacity to adapt to metabolic pressure across the lifespan.

“We found that ageing in the pancreas is not just a process of decline, but one of constant adjustment,” said Avrahami-Tzfati.

“Beta cells are essentially running a marathon to keep blood sugar stable. They can do this remarkably well for decades – but in T2DM, that marathon turns into a sprint,” she said.

In individuals with T2DM, the researchers observed additional demethylation in beta cells compared with cells from people without diabetes. This finding suggested that the adaptive mechanism seen during healthy ageing may become intensified when beta cells face chronic metabolic stress. In the early stages of disease development, this response may help the body to maintain insulin production despite rising insulin resistance.

However, the study also suggested that this compensatory process has limits. Under prolonged stress, beta cells may no longer sustain the level of insulin output required to maintain normal glucose regulation. As their functional capacity declines, blood glucose rises and T2DM progresses. This interpretation reframes T2DM not simply as an abrupt failure of insulin production but as the eventual breakdown of a long-running adaptive response.

The findings are clinically important because diabetes is a major cause of cardiovascular disease, kidney failure, visual impairment and premature mortality. The condition also places substantial pressure on healthcare systems and is becoming more common as populations age. A better understanding of beta-cell resilience may therefore support efforts to delay disease progression, preserve insulin secretion and identify therapeutic windows before irreversible decline occurs.

“This study shows that mechanisms that help beta cells adapt throughout life may also be engaged more strongly under chronic stress. Understanding this balance points to future research aimed at preserving beta-cell function and slowing disease progression,” Kaestner said.

Because the adaptive mechanism was most evident in beta cells, it may offer a promising direction for future therapeutic research. Scientists may be able to investigate ways to reduce chronic metabolic stress on beta cells, preserve beta-cell identity and long-term function, and identify the point at which adaptation begins to shift towards dysfunction.

For further reading please visit: 10.1038/s42255-026-01495-y